Bordetella pertussis is a human pathogen, Gram-negative bacteria causative agent of whooping cough. It secretes several virulence factors including adhesins which consist filamentous hemagglutinin (FHA), pertactin (PRN) and toxins such as tracheal cytotoxin, pertussis toxin (PT), and adenylate cyclase-hemolysin (AC-Hly), allowing it to multiply and colonize the human respiratory epithelium (
1)
. Among them, adenylate cyclase toxin (CyaA) is a major virulence factor of
B. Pertussis and anti-CyaA antibodies are present in sera from convalescent patients and patients vaccinated with WCVs (
2,
3). CyaA is a 177 kDa protein endowed with adenylate cyclase (AC) activity and with the ability to invade and intoxicate mammalian cells (
4).
Upon entry into the cell, the N-terminal AC enzymic moiety is activated by host calmodulin to produce supraphysiological levels of cyclic AMP (cAMP). In immune effector cells, it impairs their phagocytic and bactericidal capabilities and induces apoptosis, features which are assumed to assist survival of the bacteria in the initial stages of respiratory tract colonisation (
5). At high concentrations, CyaA forms pores or channels which make the toxin cytolytic (
4). Anti-CyaA antibodies have been shown to enhance phagocytosis of
B. Pertussis through neutralisation of CyaA which, normally inhibits phagocytosis by neutrophil polymorphonuclear leukocytes (
6,
7). An immune response to this toxin might therefore be useful to prevent colonisation of the host by
B. Pertussis. Immunisation with CyaA, purified from
B. Pertussis or in recombinant form from
Escherichia coli, protected mice against intranasal challenge with virulent
B. Pertussis (
8-10). In addition, co-administration of CyaA or CyaA*, a derivative lacking AC enzymic activity, with an ACV indicated the enhancement of the protective effects of an ACV in mice (
11).